S.Korea's SK bioscience to invest $132 mln to boost vaccine production

SK Bioscience Co

21/06/2021 05:15

SEOUL, June 21 (Reuters) - South Korea's SK bioscience
 302440.KS  said on Monday it plans to expand vaccine production
by investing about 150 billion won ($132 million) by 2024 to add
production capacity, as well as equipping its plant to make
newer mRNA and viral vector vaccines.  
    The vaccine maker said in a statement it has signed an
agreement with the government of North Gyeongsang Province and
the city of Andong, about 190 km (118 miles) southeast of Seoul,
to expand its plant there and buy new land. 
    SK bioscience said it plans to add some 99,130 square metres
of additional production space in the area.
    Its Andong plant produces COVID-19 vaccines developed by
AstraZeneca Plc  AZN.L  and Novavax Inc  NVAX.O . 
    The company said last week the facility had received
European Union Good Manufacturing Practices (GMP) certification,
enabling SK to export vaccines to Europe.  urn:newsml:reuters.com:*:nL3N2N40W5

($1 = 1,138.5300 won)

 (Reporting by Joyce Lee; editing by Richard Pullin)
 ((jungyoon.lee@tr.com; +82 2 6936 1467;))